GSK (NYSE:GSK - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of $0.44 per share and revenue of $7.75 billion for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.
GSK Price Performance
GSK stock traded down $0.11 during midday trading on Wednesday, reaching $34.99. 3,563,921 shares of the stock traded hands, compared to its average volume of 3,951,085. The stock has a market cap of $72.52 billion, a P/E ratio of 22.74, a PEG ratio of 1.31 and a beta of 0.63. The stock's fifty day moving average is $33.98 and its 200-day moving average is $37.75. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. GSK has a 12 month low of $31.72 and a 12 month high of $45.92.
Analysts Set New Price Targets
GSK has been the topic of several research reports. StockNews.com cut shares of GSK from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, January 21st. Jefferies Financial Group cut shares of GSK from a "buy" rating to a "hold" rating and decreased their target price for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered GSK from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Finally, Guggenheim cut shares of GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. Six analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, GSK currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.
Get Our Latest Stock Report on GSK
GSK Company Profile
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Read More
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
